- Home
- CMC vs PCVX Comparison
CMC vs PCVX Comparison
Compare CMC & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMC
- PCVX
- Stock Information
- Founded
- CMC 1915
- PCVX 2013
- Country
- CMC United States
- PCVX United States
- Employees
- CMC N/A
- PCVX N/A
- Industry
- CMC Steel/Iron Ore
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- CMC Industrials
- PCVX Health Care
- Exchange
- CMC Nasdaq
- PCVX Nasdaq
- Market Cap
- CMC 5.5B
- PCVX 4.4B
- IPO Year
- CMC 1987
- PCVX 2020
- Fundamental
- Price
- CMC $52.13
- PCVX $35.76
- Analyst Decision
- CMC Buy
- PCVX Strong Buy
- Analyst Count
- CMC 7
- PCVX 10
- Target Price
- CMC $58.42
- PCVX $136.50
- AVG Volume (30 Days)
- CMC 1.1M
- PCVX 1.5M
- Earning Date
- CMC 06-23-2025
- PCVX 08-05-2025
- Dividend Yield
- CMC 1.38%
- PCVX N/A
- EPS Growth
- CMC N/A
- PCVX N/A
- EPS
- CMC 0.32
- PCVX N/A
- Revenue
- CMC $7,680,111,000.00
- PCVX N/A
- Revenue This Year
- CMC N/A
- PCVX N/A
- Revenue Next Year
- CMC $8.14
- PCVX N/A
- P/E Ratio
- CMC $165.14
- PCVX N/A
- Revenue Growth
- CMC N/A
- PCVX N/A
- 52 Week Low
- CMC $37.92
- PCVX $27.66
- 52 Week High
- CMC $64.53
- PCVX $121.06
- Technical
- Relative Strength Index (RSI)
- CMC 60.28
- PCVX 57.77
- Support Level
- CMC $50.91
- PCVX $31.79
- Resistance Level
- CMC $53.59
- PCVX $36.89
- Average True Range (ATR)
- CMC 1.30
- PCVX 1.51
- MACD
- CMC 0.16
- PCVX 0.37
- Stochastic Oscillator
- CMC 77.64
- PCVX 77.65
About CMC Commercial Metals Company
Commercial Metals Co operates steel mills, steel fabrication plants, and metal recycling facilities in the United States and manufactures rebar and structural steel, which are key product categories for the nonresidential construction sector. The Company has three operating and reportable segments: North America Steel Group, Europe Steel Group and Emerging Businesses Group.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.